© Reuters. FILE PHOTO: Coronavirus disease (COVID-19) vaccination campaign in Stains


By Michael Erman

NEW YORK (Reuters) – Pfizer Inc (NYSE:) and BioNTech SE (NASDAQ:) will exceed their original global target for COVID-19 vaccines by as much as 20% this year, producing 2.3 billion to 2.4 billion doses, Pfizer Chief Executive Albert Bourla said on Thursday.

“We will exceed clearly, this year, the 2 billion doses,” Bourla said in an interview.

By the fourth quarter, the companies will be at a 3 billion dose a year run rate, and should be able to produce that much next year, he added.

Bourla said the company expects to be able to meet its commitment of supplying 120 million doses of its vaccine to the U.S. government by the end of March. That would require them to deliver another 60 million doses over the next three weeks.

“Those have already been manufactured” and are currently being tested for quality, he said.

“Unless a batch (of vaccine) fails, we will be able to provide them. Our track record is that our batches don’t fail,” he said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link